Skip to content

Insight, China's Pharmaceutical Industry

Fineline Insights, Pharma Clarity

  • Home
  • About US
  • Bioinsight
  • Policy Hub
  • Deals Book
  • Privacy Policy
  • Contact US

Header Toggle Sidebar

This is an example widget to show how the Header Toggle Sidebar looks by default. You can add custom widgets from the widgets in the admin.

Company Deals

Harbour BioMed Boosts Spruce Stake to 3.8%, Advancing SPR202 for Adrenal Disease

Fineline Cube Jan 19, 2026
Company Deals

InventisBio Files for Hong Kong IPO, Betting on Oncology and Metabolic Pipeline

Fineline Cube Jan 16, 2026
Company Deals

Boston Scientific to Acquire Penumbra in $14.5 Billion Deal, Bolsters Thrombectomy Leadership

Fineline Cube Jan 16, 2026
Company Deals

J&J MedTech Partners with CED Medical to Accelerate Neurovascular Intervention Solutions

Fineline Cube Jan 16, 2026
Company Deals

Cardiac Bio Solutions Launches MyCardia AT China Production with Shenzhen Ebulent

Fineline Cube Jan 16, 2026
Policy / Regulatory

NHSA Releases NRDL Value Assessment Guidelines, Prioritizing 8 Drug Categories for Real‑World Evaluation

Fineline Cube Jan 15, 2026
Company Drug

Duality’s DB‑1317 ADC Receives IND Approval for ADAM9‑Targeted Solid Tumor Therapy

Fineline Cube Jan 19, 2026
Company Drug

Biogen’s High‑Dose SPINRAZA Wins EU Approval for 5q SMA After Japan Nod

Fineline Cube Jan 19, 2026
Company Drug

AstraZeneca and Daiichi Sankyo’s Enhertu Secures FDA Approval for HER2-Positive Solid Tumors

Fineline Cube Apr 8, 2024

Partners AstraZeneca (AZ; NASDAQ: AZN) and Daiichi Sankyo (TYO: 4568) have been granted an additional...

Company Drug

Bristol Myers Squibb’s Abecma Receives FDA Approval for Wider Use in Multiple Myeloma Treatment

Fineline Cube Apr 8, 2024

The US Food and Drug Administration (FDA) has granted an indication extension for Bristol Myers...

Company

Sanofi Announces Sweeping Restructuring and Layoffs in Pipeline Reprioritization Effort

Fineline Cube Apr 8, 2024

Paris-based pharmaceutical giant Sanofi (NASDAQ: SNY) is embarking on a comprehensive “full pipeline reprioritization” that...

Company Drug

Dizal Pharmaceutical’s Sunvozertinib Earns FDA Breakthrough Therapy Designation for NSCLC

Fineline Cube Apr 8, 2024

Dizal Pharmaceutical Co., Ltd (SHA: 688192), a leading Chinese pharmaceutical company, has announced that its...

Company Deals

Sino Biopharmaceutical Partners with Boehringer Ingelheim to Bring Innovative Cancer Therapies to China

Fineline Cube Apr 8, 2024

Sino Biopharmaceutical Ltd (HKG: 1177) has announced a strategic partnership with Germany’s Boehringer Ingelheim (BI)...

Company Drug

Sichuan Kelun-Biotech Presents Positive Results for Sacituzumab Tirumotecan at AACR 2024

Fineline Cube Apr 8, 2024

Sichuan Kelun-Biotech Biopharmaceutical Co., Ltd (HKG: 6990) has announced the presentation of favorable results from...

Company Deals R&D

Zhejiang Dian Diagnostics Partners with Hangzhou Medical College to Establish Education Base

Fineline Cube Apr 8, 2024

Zhejiang Dian Diagnostics Co., Ltd (SHE: 300244), a prominent player in the medical diagnostics space,...

Company Deals

Applied Protein Technology Secures Series C Financing to Accelerate Multi-Omics Innovation

Fineline Cube Apr 8, 2024

Shanghai-based Applied Protein Technology (APTBIO), a pioneer in life science technology services driven by mass...

Company Drug

Huadong Medicine Gets NMPA Approval for Clinical Trial of FRα-Targeting ADC Elahere

Fineline Cube Apr 8, 2024

China-based Huadong Medicine Co., Ltd (SHE: 000963) has announced that it has received approval from...

Company Drug

Hinova Pharmaceuticals Receives NMPA Greenlight for HP501 Clinical Trial in Gout Patients

Fineline Cube Apr 8, 2024

Shanghai-based Hinova Pharmaceuticals Inc. (SHA: 688302) has announced that it has received approval from the...

Company Drug

Junshi Biosciences’ Toripalimab Approved for First-Line RCC Treatment in China

Fineline Cube Apr 8, 2024

Shanghai Junshi Biosciences Co., Ltd (HKG: 1877; SHA: 688180) has received a new indication approval...

Company Drug

Ascletis Pharma Halts ASC42 Phase II Study in Primary Biliary Cholangitis

Fineline Cube Apr 7, 2024

China-based Ascletis Pharma Inc. (HKG: 1672) has announced its decision to terminate the Phase II...

Company Drug

IASO Biotherapeutics Gains FDA Nod for Fucaso CAR-T Study in Myasthenia Gravis

Fineline Cube Apr 7, 2024

China-based IASO Biotherapeutics has received approval from the U.S. Food and Drug Administration (FDA) to...

Company Drug

Ipsen Secures NMPA Approval for Somatuline in Advanced Neuroendocrine Tumors

Fineline Cube Apr 7, 2024

Ipsen (EPA: IPN; OTCMKTS: IPSEY), a France-based biopharmaceutical company, has received new indication approval from...

Company Drug

Shanghai Henlius Reports Phase III Success for HLX14 in Osteoporosis Treatment

Fineline Cube Apr 7, 2024

Shanghai Henlius Biotech Inc. (HKG: 2696), based in China, has announced that its global, multi-center...

Company Deals

Siemens Healthineers and Siemens China Partner with Fudan Hospital Logistic Service on Green Imaging Centers

Fineline Cube Apr 7, 2024

Germany-based Siemens Healthineers AG, along with its subsidiary Siemens China, has entered into a strategic...

Company Drug

Mabwell Bioscience Receives NMPA Approval for Biosimilar Version of Amgen’s Xgeva

Fineline Cube Apr 7, 2024

Mabwell (Shanghai) Bioscience Co., Ltd (SHA: 688062) has announced that it has received market approval...

Company Drug

Walvax Biotechnology’s COVID-19 Variant Vaccine RQ3033 Shows Positive Phase III Results

Fineline Cube Apr 7, 2024

China-based Walvax Biotechnology Co., Ltd (SHE: 300142) has announced positive results from a Phase III...

Company Deals

Eisai Forges Strategic Partnership with China Resource Medicine and China Resources Sanjiu for Pharmaceutical Collaboration

Fineline Cube Apr 7, 2024

Japanese pharmaceutical company Eisai (TYO: 4523) has entered into a cooperation agreement with China Resource...

Company Drug

Legend Biotech’s Carvykti Secures FDA Approval for Expanded Use in Multiple Myeloma

Fineline Cube Apr 7, 2024

China-based Legend Biotech Corporation (NASDAQ: LEGN) has announced that the US Food and Drug Administration...

Posts pagination

1 … 323 324 325 … 611

Recent updates

  • Harbour BioMed Boosts Spruce Stake to 3.8%, Advancing SPR202 for Adrenal Disease
  • Duality’s DB‑1317 ADC Receives IND Approval for ADAM9‑Targeted Solid Tumor Therapy
  • Biogen’s High‑Dose SPINRAZA Wins EU Approval for 5q SMA After Japan Nod
  • InventisBio Files for Hong Kong IPO, Betting on Oncology and Metabolic Pipeline
  • Boston Scientific to Acquire Penumbra in $14.5 Billion Deal, Bolsters Thrombectomy Leadership
Special Report 2025 Q1: U.S. Targets Chinese Pharma with 200% Tariffs—Will the Global Drug Market Collapse?

Category

  • Company
  • Deals
  • Digital
  • Drug
  • General/Other
  • Hospital
  • Legal / IP
  • Medical Device
  • Others
  • Policy / Regulatory
  • R&D

You Missed

Company Deals

Harbour BioMed Boosts Spruce Stake to 3.8%, Advancing SPR202 for Adrenal Disease

Company Drug

Duality’s DB‑1317 ADC Receives IND Approval for ADAM9‑Targeted Solid Tumor Therapy

Company Drug

Biogen’s High‑Dose SPINRAZA Wins EU Approval for 5q SMA After Japan Nod

Company Deals

InventisBio Files for Hong Kong IPO, Betting on Oncology and Metabolic Pipeline

Insight, China's Pharmaceutical Industry

Fineline Insights, Pharma Clarity

Copyright © 2025 | Fineline Information & Technology | BlogData by Themeansar.